Cell No. : Cell Name
RCB5977 : HCT116 CERT1 KO
update : 2025/01/16
|
Comment | Currently not ready. |
Comment from the depositor | A mutant cell line was developed in the human colon carcinoma-derived HCT 116 cell line, in which the CERT1 gene encoding the ceramide transport protein was disrupted using the CRISPR/Cas9 technology. |
Terms and conditions | |
Remarks | CRISPR/Cas9 genome edited bioresources Announcement of bioresources developed by the CRISPR/Cas9 technology. |
Order Form |
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
Basic information
|
Expected time |
Upon a request we will start preparation. Contact us: cellkitaku.brc@riken.jp
|
IPR |
National Institute of Infectious Diseases (Japan)
|
Depositor |
HANADA, Kentaro
|
Reference information |
Reference |
2
|
User's Publication |
0
|
Reference |
21780
Tamura N, Sakai S, Martorell L, Colomé R, Mizuike A, Goto A, Ortigoza-Escobar JD, Hanada K.
Intellectual disability-associated mutations in the ceramide transport protein gene CERT1 lead to aberrant function and subcellular distribution.
J Biol Chem
2021
101338
PubMed ID: 34688657
DOI: 10.1016/j.jbc.2021.101338
|
21779
Murakami H, Tamura N, Enomoto Y, Shimasaki K, Kurosawa K, Hanada K.
Intellectual disability-associated gain-of-function mutations in CERT1 that encodes the ceramide transport protein CERT.
PLoS One
2020
15(12):e0243980
PubMed ID: 33347465
DOI: 10.1371/journal.pone.0243980
|